Circulating microRNA as new prognostic markers in chronic myeloid leukemia

• Grant number: 11/50629-7
• Support Opportunities: Regular Research Grants
• Start date: July 01, 2011
• End date: September 30, 2013
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Paula de Oliveira Montandon Hokama
• Grantee: Paula de Oliveira Montandon Hokama
• Host Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Chronic Myeloid Leukemia (CML) is a malignant clonal hematopoietic stem cell disease. The discovery of the Philadelphia chromosome and subsequent identification of the gene bcr-abl have led to understanding the biology of the disease and the development of target-specific drugs, as well as molecular methods for monitoring the disease. The current focus of research in the CML is facing the greatest understanding of the molecular and epigenetic mechanisms that lead to therapy resistance and disease progression. Recent studies show that the expression of specific microRNAs modulates oncogenes and tumor suppressor genes involved in cancer developrnent. We are proposing a new study in the literature that seeks to identify the profile of micro-RNAs of patients who respond well to first-line treatments for CML. We wiU evaluate the profile of microRNAs in 48 CML patients who achieved complete cytogenetic response (absence ofPhiladelphia cbromosome) after treatment. This study will compared 24 patients over one year of allogeneic bone marrow transplantation and 24 patients using inhibitor of tyrosine. The microRNAs expression levels are going to be detected by quantitative real time PCR (Human 96-miScript Assay Qiagen). The aim of our study is to explore which microRNAs are unique for the two difIerent CML treated patient group. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

MARTINS, JULIANA RAVELLI BALDASSARRE; MORAES, LEONARDO NAZARIO DE; CURY, SARAH SANTILONI; DADALTO, JULIANE; CAPANNACCI, JULIANA; CARVALHO, ROBSON FRANCISCO; NOGUEIRA, CELIA REGINA; HOKAMA, NEWTON KEY; HOKAMA, PAULA DE OLIVEIRA MONTANDON. Comparison of microRNA Expression Profile in Chronic Myeloid Leukemia Patients Newly Diagnosed and Treated by Allogeneic Hematopoietic Stem Cell Transplantation. FRONTIERS IN ONCOLOGY, v. 10, SEP 4 2020. (11/50629-7)

MUNIZ FERREIRA, LETICIA ANTUNES; CAPANNACCI, JULIANA; HOKAMA, NEWTON KEY; NOGUEIRA, CELIA REGINA; CECCARELLI, MICHELE; CERULO, LUIGI; D'ANGELO, FULVIO; MONTANDON HOKAMA, PAULA DE OLIVEIRA. Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase - chronic myeloid leukemia. Leukemia & Lymphoma, v. 60, n. 3, p. 805-811, FEB 23 2019. (11/50629-7)

MARTINS, JULIANA R. B.; MORAES, LEONARDO N.; CURY, SARAH S.; CAPANNACCI, JULIANA; CARVALHO, ROBSON FRANCISCO; NOGUEIRA, CELIA REGINA; HOKAMA, NEWTON KEY; HOKAMA, PAULA O. M.. MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v. 22, n. 19, OCT 2021. (11/50629-7)